| 67.96 -0.21 (-0.31%) | 03-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 84.75 | 1-year : | 93.44 |
| Resists | First : | 72.56 | Second : | 80 |
| Pivot price | 73.36  |
|||
| Supports | First : | 60.54 | Second : | 50.36 |
| MAs | MA(5) : | 70.7 |
MA(20) : | 70.97 |
| MA(100) : | 73.47 |
MA(250) : | 58.92 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.9 |
| %K %D | K(14,3) : | 30.7 |
D(3) : | 45.9 |
| RSI | RSI(14): 42.6 |
|||
| 52-week | High : | 85.25 | Low : | 38.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TARS ] has closed above bottom band by 5.0%. Bollinger Bands are 5.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 69.2 - 69.68 | 69.68 - 70.05 |
| Low: | 66.23 - 66.89 | 66.89 - 67.39 |
| Close: | 67.05 - 67.94 | 67.94 - 68.62 |
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Wed, 11 Mar 2026
TARS: Rapid growth, strong guidance, and a large untapped market drive optimism for future performance - TradingView
Tue, 10 Mar 2026
The Bull Case For Tarsus Pharmaceuticals (TARS) Could Change Following First 2026 XDEMVY Sales Outlook - Sahm
Mon, 09 Mar 2026
Stock option and RSU grants for Tarsus (NASDAQ: TARS) executive - Stock Titan
Mon, 09 Mar 2026
Tarsus (TARS) CHRO granted 27,310 options and 17,161 RSUs - Stock Titan
Mon, 09 Mar 2026
Tarsus (TARS) CEO Bobak Azamian granted stock options and RSUs with multi-year vesting - Stock Titan
Mon, 09 Mar 2026
Total debt per share of Tarsus Pharmaceuticals, Inc. – BX:TARS - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 43 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 3 (%) |
| Held by Institutions | 107.5 (%) |
| Shares Short | 5,460 (K) |
| Shares Short P.Month | 5,370 (K) |
| EPS | -1.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.06 |
| Profit Margin | -14.8 % |
| Operating Margin | -5.3 % |
| Return on Assets (ttm) | -9.5 % |
| Return on Equity (ttm) | -23.4 % |
| Qtrly Rev. Growth | 128.3 % |
| Gross Profit (p.s.) | 8.37 |
| Sales Per Share | 10.6 |
| EBITDA (p.s.) | -1.63 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -42.75 |
| PEG Ratio | 0 |
| Price to Book value | 8.42 |
| Price to Sales | 6.4 |
| Price to Cash Flow | -232.32 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|